Accueil   Diary - News   All news NEURONAX obtains the authorization to start its phase I clinical trial in France and Belgium and strengthens its patent portfolio

NEURONAX obtains the authorization to start its phase I clinical trial in France and Belgium and strengthens its patent portfolio

 

Saint-Beauzire, Lyon, February 28, 2017, NEURONAX, the biopharmaceutical company specialized in neuronal regeneration, has been authorized to start its Phase I clinical trial by the Healthcare Authorities (French National Agency for Medicines and Health Products Safety (ANSM) for France and The Federal Agency for Medicines and Health Products (FAMHP) for Belgium).

 


This first clinical trial in humans with the NX210 product is titled " A Phase I Study to Investigate the Safety and Potential Activity of Single Intrathecal Administration of NX210 in Patients with Spinal Cord Injury ".

 

The primary endpoint of this study is to evaluate the safety of NX210 in patients with acute spinal cord injury. Secondary and exploratory endpoints include biological effectiveness of the experimental drug and functional recovery.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree